A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy

James E. Tisdale, Heather A. Wroblewski, Donna S. Wall, Karen M. Rieger, Zane T. Hammoud, Jerry V. Young, Kenneth A. Kesler

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Objective: Atrial fibrillation is common after esophagectomy. The objective of this study was to determine the efficacy and safety of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. Methods: Eighty patients undergoing transthoracic esophagectomy were randomly, prospectively assigned to receive amiodarone (n = 40) or no prophylaxis (control group, n = 40). Amiodarone-treated patients received the drug by continuous infusion, initiated at the time of induction of anesthesia, at a rate of 0.73 mg/min (43.75 mg/h), and continued for 96 hours (total dose 4200 mg). The primary end point was atrial fibrillation requiring treatment. Secondary end points included any atrial fibrillation lasting longer than 30 seconds and postoperative hospital and intensive care unit stays. Results: There were no significant differences between the amiodarone and control groups in demographic characteristics, comorbid conditions, or preoperative or postoperative use of β-blockers or calcium-channel blockers. The incidence of atrial fibrillation requiring treatment was lower in the amiodarone group than in the control group (15% vs 40%, P = .02, relative risk reduction 62.5%). There were no significant differences between the amiodarone and control groups in median hospital stay (11 days vs 12 days, P = .31) or median intensive care unit stay (68 hours vs 77 hours, p = .097). There were no significant difference between the groups in the incidences of adverse effects. Conclusions: Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic esophagectomy.

Original languageEnglish (US)
Pages (from-to)45-51
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume140
Issue number1
DOIs
StatePublished - Jul 1 2010

Fingerprint

Esophagectomy
Amiodarone
Atrial Fibrillation
Control Groups
Intensive Care Units
Incidence
Postoperative Care
Calcium Channel Blockers
Risk Reduction Behavior
Length of Stay
Anesthesia
Demography
Safety
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. / Tisdale, James E.; Wroblewski, Heather A.; Wall, Donna S.; Rieger, Karen M.; Hammoud, Zane T.; Young, Jerry V.; Kesler, Kenneth A.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 140, No. 1, 01.07.2010, p. 45-51.

Research output: Contribution to journalArticle

Tisdale, James E. ; Wroblewski, Heather A. ; Wall, Donna S. ; Rieger, Karen M. ; Hammoud, Zane T. ; Young, Jerry V. ; Kesler, Kenneth A. / A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. In: Journal of Thoracic and Cardiovascular Surgery. 2010 ; Vol. 140, No. 1. pp. 45-51.
@article{12a950123b48444c9d21bc6828e469b9,
title = "A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy",
abstract = "Objective: Atrial fibrillation is common after esophagectomy. The objective of this study was to determine the efficacy and safety of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. Methods: Eighty patients undergoing transthoracic esophagectomy were randomly, prospectively assigned to receive amiodarone (n = 40) or no prophylaxis (control group, n = 40). Amiodarone-treated patients received the drug by continuous infusion, initiated at the time of induction of anesthesia, at a rate of 0.73 mg/min (43.75 mg/h), and continued for 96 hours (total dose 4200 mg). The primary end point was atrial fibrillation requiring treatment. Secondary end points included any atrial fibrillation lasting longer than 30 seconds and postoperative hospital and intensive care unit stays. Results: There were no significant differences between the amiodarone and control groups in demographic characteristics, comorbid conditions, or preoperative or postoperative use of β-blockers or calcium-channel blockers. The incidence of atrial fibrillation requiring treatment was lower in the amiodarone group than in the control group (15{\%} vs 40{\%}, P = .02, relative risk reduction 62.5{\%}). There were no significant differences between the amiodarone and control groups in median hospital stay (11 days vs 12 days, P = .31) or median intensive care unit stay (68 hours vs 77 hours, p = .097). There were no significant difference between the groups in the incidences of adverse effects. Conclusions: Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic esophagectomy.",
author = "Tisdale, {James E.} and Wroblewski, {Heather A.} and Wall, {Donna S.} and Rieger, {Karen M.} and Hammoud, {Zane T.} and Young, {Jerry V.} and Kesler, {Kenneth A.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.jtcvs.2010.01.026",
language = "English (US)",
volume = "140",
pages = "45--51",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy

AU - Tisdale, James E.

AU - Wroblewski, Heather A.

AU - Wall, Donna S.

AU - Rieger, Karen M.

AU - Hammoud, Zane T.

AU - Young, Jerry V.

AU - Kesler, Kenneth A.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objective: Atrial fibrillation is common after esophagectomy. The objective of this study was to determine the efficacy and safety of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. Methods: Eighty patients undergoing transthoracic esophagectomy were randomly, prospectively assigned to receive amiodarone (n = 40) or no prophylaxis (control group, n = 40). Amiodarone-treated patients received the drug by continuous infusion, initiated at the time of induction of anesthesia, at a rate of 0.73 mg/min (43.75 mg/h), and continued for 96 hours (total dose 4200 mg). The primary end point was atrial fibrillation requiring treatment. Secondary end points included any atrial fibrillation lasting longer than 30 seconds and postoperative hospital and intensive care unit stays. Results: There were no significant differences between the amiodarone and control groups in demographic characteristics, comorbid conditions, or preoperative or postoperative use of β-blockers or calcium-channel blockers. The incidence of atrial fibrillation requiring treatment was lower in the amiodarone group than in the control group (15% vs 40%, P = .02, relative risk reduction 62.5%). There were no significant differences between the amiodarone and control groups in median hospital stay (11 days vs 12 days, P = .31) or median intensive care unit stay (68 hours vs 77 hours, p = .097). There were no significant difference between the groups in the incidences of adverse effects. Conclusions: Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic esophagectomy.

AB - Objective: Atrial fibrillation is common after esophagectomy. The objective of this study was to determine the efficacy and safety of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. Methods: Eighty patients undergoing transthoracic esophagectomy were randomly, prospectively assigned to receive amiodarone (n = 40) or no prophylaxis (control group, n = 40). Amiodarone-treated patients received the drug by continuous infusion, initiated at the time of induction of anesthesia, at a rate of 0.73 mg/min (43.75 mg/h), and continued for 96 hours (total dose 4200 mg). The primary end point was atrial fibrillation requiring treatment. Secondary end points included any atrial fibrillation lasting longer than 30 seconds and postoperative hospital and intensive care unit stays. Results: There were no significant differences between the amiodarone and control groups in demographic characteristics, comorbid conditions, or preoperative or postoperative use of β-blockers or calcium-channel blockers. The incidence of atrial fibrillation requiring treatment was lower in the amiodarone group than in the control group (15% vs 40%, P = .02, relative risk reduction 62.5%). There were no significant differences between the amiodarone and control groups in median hospital stay (11 days vs 12 days, P = .31) or median intensive care unit stay (68 hours vs 77 hours, p = .097). There were no significant difference between the groups in the incidences of adverse effects. Conclusions: Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic esophagectomy.

UR - http://www.scopus.com/inward/record.url?scp=77953479808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953479808&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2010.01.026

DO - 10.1016/j.jtcvs.2010.01.026

M3 - Article

C2 - 20381077

AN - SCOPUS:77953479808

VL - 140

SP - 45

EP - 51

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -